Patent intelligence · US
US 8937082
Nilotinib salts and crystalline forms thereof
Nilotinib salts and crystalline forms thereof
Patent details — US 8937082
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 20, 2015
- Expiration
- Jan 15, 2035
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 29
- CPC classes
- A61K, A61K31/4178, A61K31/506, A61P
Quick answer
US 8937082 (Nilotinib salts and crystalline forms thereof) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Jan 20, 2015. Expires Jan 15, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/4178, A61K31/506, A61P, A61P35/00, A61P35/02
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Related coverage
FDA Approves Oral Nilotinib Tablets for Ph+ CML: A New Era for Treatment
The FDA has approved oral nilotinib tablets, a significant advancement for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This approval offers a new, more convenient treatment option and impacts the competitive dynamics within the CML market.
FDA Approves Orally Disintegrating Nilotinib (Cavhanza) for Chronic Myeloid Leukemia
The FDA has approved Cavhanza, an orally disintegrating tablet (ODT) formulation of nilotinib, for the treatment of select patients with chronic myeloid leukemia (CML). This new formulation enhances patient convenience by allowing co-administration with acid-reducing agents and reducing food-related burdens.
Frequently asked questions
What is US patent 8937082?
US 8937082 (Nilotinib salts and crystalline forms thereof) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Jan 20, 2015. Expires Jan 15, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8937082?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8937082 expire?
Our index shows an expiration date of Jan 15, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.